David Risinger, an analyst from Leerink Partners, maintained the Hold rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target was raised to $55.00. David Risinger has given ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report) and Envista ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

Pharmaceutical giant Bristol Myers Squibb (BMY) raises its full-year earnings guidance after topping third quarter estimates, ...

Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...

With a 20% increase in growth portfolio revenue and strategic cost savings, Bristol-Myers Squibb Co (BMY) raises its ...

The pharmaceutical company posted third-quarter adjusted earnings a share of $1.80 on revenue of $11.9 billion.

Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis.

Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as ...

Bristol Myers Squibb (BMY) is set to announce Q3 earnings. Analysts expect profit of $1.50 per share on revenue of $11.25B.

Lawyers for AstraZeneca , Bristol Myers Squibb and Johnson & Johnson's Janssen on Wednesday urged a federal appeals court in ...